1. Emergence of novel Leptospira serovars: a need for adjusting vaccination policies for dogs?
- Author
-
Arent ZJ, Andrews S, Adamama-Moraitou K, Gilmore C, Pardali D, and Ellis WA
- Subjects
- Agglutination Tests veterinary, Animals, Antibodies, Bacterial blood, Communicable Diseases, Emerging epidemiology, Communicable Diseases, Emerging prevention & control, Dog Diseases microbiology, Dog Diseases prevention & control, Dogs microbiology, Female, Greece epidemiology, Leptospirosis epidemiology, Leptospirosis microbiology, Leptospirosis prevention & control, Male, Practice Guidelines as Topic standards, Bacterial Vaccines therapeutic use, Communicable Diseases, Emerging veterinary, Dog Diseases epidemiology, Leptospira, Leptospirosis veterinary
- Abstract
A total of 855 sera from dogs in Greece were tested for antibodies to strains belonging to the Pomona, Grippotyphosa and Australis serogroups of Leptospira to assess exposure levels to these serogroups, possible associations with clinical disease and to evaluate whether these findings support the inclusion of additional serovars in dog vaccines. Antibodies were detected in 110 (12·9%) dogs. The highest seroprevalence (4·9%) was to the proposed novel serovar Altodouro belonging to the Pomona serogroup. This serovar also showed a statistically significant association with clinical disease. Serovar Bratislava antibodies were found in 3·4% of sera. Consideration should be given to the inclusion of serovars belonging to the Pomona serogroup and serovar Bratislava in future dog vaccines for the Greek market.
- Published
- 2013
- Full Text
- View/download PDF